Trastuzumab-induced cardiac dysfunction

被引：15
作者：
Panjrath, Gurusher Singh
Jain, Diwakar
机构：
[1] Drexel Univ, Coll Med, Nucl Cardiovasc Imaging Lab, Philadelphia, PA 19102 USA
[2] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Dept Internal Med, New York, NY USA
来源：
NUCLEAR MEDICINE COMMUNICATIONS | 2007年 / 28卷 / 02期
关键词：
METASTATIC BREAST-CANCER; PHASE-II TRIAL; INDUCED CARDIOTOXICITY; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; SAFETY; THERAPY; EFFICACY; HER2; VINORELBINE;
D O I：
10.1097/MNM.0b013e328025ae04
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：69 / 73
页数：5
相关论文
共 35 条
[1]   Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: Findings from a case series [J].
Ardavanis, A ;
Tryfonopoulos, D ;
Orfanos, G ;
Karamouzis, M ;
Scorilas, A ;
Alexopoulos, A ;
Rigatos, G .
ONKOLOGIE, 2005, 28 (11) :558-564
[2]  
Behr TM, 2001, NEW ENGL J MED, V345, P995
[3]   Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study [J].
Bengala, C ;
Zamagni, C ;
Pedrazzoli, P ;
Matteucci, P ;
Ballestrero, A ;
Da Prada, G ;
Martino, M ;
Rosti, G ;
Danova, M ;
Bregni, M ;
Jovic, G ;
Guarneri, V ;
Maur, M ;
Conte, PF .
BRITISH JOURNAL OF CANCER, 2006, 94 (07) :1016-1020
[4]   Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm [J].
Burstein, HJ ;
Harris, LN ;
Marcom, PK ;
Lambert-Falls, R ;
Havlin, K ;
Overmoyer, B ;
Friedlander, RJ ;
Gargiulo, J ;
Strenger, R ;
Vogel, CL ;
Ryan, PD ;
Ellis, MJ ;
Nunes, RA ;
Bunnell, CA ;
Campos, SM ;
Hallor, M ;
Gelman, R ;
Winer, EP .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2889-2895
[5]   Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study [J].
Burstein, HJ ;
Harris, LN ;
Gelman, R ;
Lester, SC ;
Nunes, RA ;
Kaelin, CM ;
Parker, LM ;
Ellisen, LW ;
Kuter, I ;
Gadd, MA ;
Christian, RL ;
Kennedy, PR ;
Borges, VF ;
Bunnell, CA ;
Younger, J ;
Smith, BL ;
Winer, EP .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :46-53
[6]   Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial [J].
Chia, Stephen ;
Clemons, Mark ;
Martin, Lee-Ann ;
Rodgers, Angela ;
Gelmon, Karen ;
Pond, Gregory R. ;
Panasci, Lawrence .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2773-2778
[7]   Docus on research: Herceptin and the heart - A molecular modifier of cardiac failure [J].
Chien, KR .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :789-790
[8]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[9]   Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer [J].
Cook-Bruns, N .
ONCOLOGY, 2001, 61 :58-66
[10]   Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity [J].
Ewer, MS ;
Lippman, SM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2900-2902
1234